Compounds > niacinamide

niacinamide and phosphorylcholine

niacinamide has been researched along with phosphorylcholine in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sanderson, CJ; Thomas, JA1
Bhujwalla, ZM; Glickson, JD; Shungu, DC1
Samlowski, W; Vogelzang, NJ; Weissman, A1
Anichini, A; Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mortarini, R1
Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D1
Anichini, A; Carlo-Stella, C; Corradini, P; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Giordano, L; Guidetti, A; Locatelli, SL; Malorni, W; Marchianò, A; Mortarini, R; Russo, D; Sorasio, R; Viviani, S1
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW1

Trials

1 trial(s) available for niacinamide and phosphorylcholine

ArticleYear
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Nov-15, Volume: 20, Issue:22

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Sorafenib; Treatment Outcome; Young Adult

2014

Other Studies

6 other study(ies) available for niacinamide and phosphorylcholine

ArticleYear
The mechanism of K cell (antibody-dependent) cell mediated cytotoxicity. I. The release of different cell components.
    Proceedings of the Royal Society of London. Series B, Biological sciences, 1977, Jul-20, Volume: 197, Issue:1129

    Topics: Animals; Cell Line; Chromium Radioisotopes; Cytotoxicity Tests, Immunologic; DNA, Neoplasm; Immunity, Cellular; In Vitro Techniques; Mast-Cell Sarcoma; Mice; Neoplasms, Experimental; Niacinamide; Phosphorylcholine; Rats; Rubidium; Spleen

1977
Effects of blood flow modifiers on tumor metabolism observed in vivo by proton magnetic resonance spectroscopic imaging.
    Magnetic resonance in medicine, 1996, Volume: 36, Issue:2

    Topics: Animals; Antihypertensive Agents; Glycerylphosphorylcholine; Hydralazine; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Niacinamide; Oxygen Consumption; Phosphorylcholine; Regional Blood Flow

1996
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors

2009
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Leukemia, 2013, Volume: 27, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitogen-Activated Protein Kinases; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2013
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    British journal of haematology, 2013, Volume: 161, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured

2013
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; DNA Transposable Elements; Drug Synergism; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Sorafenib; Tumor Suppressor Protein p53

2015